American Heart Journal
Volume 157, Issue 5 , Pages 899-907 , May 2009

The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents

  • Michelle J. Butler, MB, BS

      Affiliations

    • Department of Cardiology at the Alfred Hospital, Melbourne, Victoria, Australia
    • ,
  • David Eccleston, MB, BS

      Affiliations

    • Department of Cardiology at the Royal Melbourne Hospital, Melbourne, Victoria, Australia
    • ,
  • David J. Clark, MB, BS

      Affiliations

    • Department of Cardiology at the Austin Hospital, Melbourne, Victoria, Australia
    • ,
  • Andrew E. Ajani, MB, BS, MD

      Affiliations

    • Department of Cardiology at the Royal Melbourne Hospital, Melbourne, Victoria, Australia
    • Department of Epidemiology and Preventative Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia
    • ,
  • Nick Andrianopoulos, MB, BS

      Affiliations

    • Department of Epidemiology and Preventative Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia
    • ,
  • Angela Brennan, RN

      Affiliations

    • Department of Epidemiology and Preventative Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia
    • ,
  • Gishel New, MB, BS, PhD

      Affiliations

    • Department of Cardiology at the Box Hill Hospital, Melbourne, Victoria, Australia
    • ,
  • Alexander Black, MB, BS

      Affiliations

    • Department of Cardiology at the Geelong Hospital, Geelong, Victoria, Australia
    • ,
  • Gregory Szto, MB, BS

      Affiliations

    • Department of Cardiology at the Frankston Hospital, Melbourne, Victoria, Australia
    • ,
  • Chris M. Reid, PhD

      Affiliations

    • Department of Epidemiology and Preventative Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia
    • ,
  • Bryan P. Yan, MB, BS

      Affiliations

    • Department of Cardiology at the Royal Melbourne Hospital, Melbourne, Victoria, Australia
    • ,
  • James A. Shaw, MB, BS, PhD

      Affiliations

    • Department of Cardiology at the Alfred Hospital, Melbourne, Victoria, Australia
    • ,
  • Anthony M. Dart, BM, BCh, DPhil

      Affiliations

    • Department of Cardiology at the Alfred Hospital, Melbourne, Victoria, Australia
    • ,
  • Stephen J. Duffy, MB, BS, PhD

      Affiliations

    • Department of Cardiology at the Alfred Hospital, Melbourne, Victoria, Australia
    • Department of Epidemiology and Preventative Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia
    • Corresponding Author InformationReprint requests: Stephen J. Duffy, MB, BS, PhD, Heart Centre, Alfred Hospital, Commercial Road, Melbourne 3004, Victoria, Australia.
    • ,
  • on behalf of the Melbourne Interventional Group (MIG)

References 

  1. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215–222
  2. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–1089
  3. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671
  4. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  5. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  6. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  7. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  8. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  9. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215–1223
  10. Maisel WH. Unanswered questions—drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981–984
  11. Farb A, Boam AB. Stent thrombosis redux—the FDA perspective. N Engl J Med. 2007;356:984–987
  12. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521
  13. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  14. Ong AT, McFadden EP, Regar E, et al. Late Angiographic Stent Thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  15. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  16. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–2809
  17. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113
  18. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  19. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  20. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  21. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992–2000
  22. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001–2009
  23. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation. 2007;115:813–818
  24. Yan BP, Ajani AE, Duffy SJ, et al. Use of drug-eluting stents in Victorian public hospitals. Med J Aust. 2006;185:363–367
  25. Ajani AE, Szto G, Duffy SJ, et al. The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project. Heart Lung Circ. 2006;15:44–47
  26. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  27. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  28. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  29. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  30. Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol. 2007;49:15–20
  31. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260–1264

PII: S0002-8703(09)00152-5

doi: 10.1016/j.ahj.2009.02.018

American Heart Journal
Volume 157, Issue 5 , Pages 899-907 , May 2009

Article Tools

* Image Usage & Resolution